Quick answer
Where is hexarelin used in the laboratory? Hexarelin is a synthetic hexapeptide agonist of the growth hormone secretagogue receptor (GHS-R1a), and published work has used it in four kinds of system: receptor binding and signaling assays in transfected cells, GH-release studies in pituitary preparations and animals, cardiac-tissue and cardiomyocyte models, and mechanistic work on the scavenger receptor CD36. Each system needs a different readout and a different negative control. The vial is a 5 mg lyophilized powder at ≥98% HPLC purity; volumes are worked out with the reconstitution calculator. For laboratory research use only; not for human consumption.
Hexarelin turns up in papers from several unrelated fields: endocrinology, cardiac physiology, receptor pharmacology and lipid biology. That spread makes it hard to tell, from a general overview, which bench system suits which question. This page is organized by experimental system rather than by molecule. For each one it describes what the published work measured, what a sensible control looks like, and what the peptide itself contributes. The compound is supplied for laboratory research use only.
What the vial contains and what that means for assay planning
The hexarelin product page lists a single 5 mg vial of lyophilized powder, purity ≥98% by HPLC, molecular formula C47H58N12O6, and the sequence His-D-2-methyl-Trp-Ala-Trp-D-Phe-Lys-NH2. The class is given as a synthetic hexapeptide GH secretagogue; the compound is also written as examorelin in the literature. Storage is 2–8 °C, with −20 °C for long-term holding, away from heat, moisture and light. Three planning consequences follow.
- The peptide is small and contains two D-residues. D-amino acids and the 2-methyl-tryptophan resist many proteases, so hexarelin is less likely than a natural peptide to be chewed up by serum enzymes during a long incubation. That does not make it immune to adsorption or oxidation.
- Two tryptophan residues are present. Tryptophan is the residue most prone to photo-oxidation, so stock tubes belong in the dark and working dilutions should be made fresh.
- Concentration is arithmetic, not a table. Stock concentration is vial mass divided by diluent volume (c = m / V). Decide the stock concentration the assay needs, then use the calculator; do not copy a figure from another lab, because assay volumes and plate formats differ.
Before any experiment, match the lot on the vial to the COA library where a certificate has been published, and note the result in the notebook. How to read a COA explains what each field means.
Where hexarelin has been used: a map of the systems
| System | Question it answers | Typical readout | Key control |
|---|---|---|---|
| Transfected cells expressing GHS-R1a | Does the ligand bind and activate the receptor? | Competition binding, intracellular calcium, inositol phosphate accumulation | Parental cells without the receptor; a reference agonist |
| Primary pituitary cells or pituitary tissue | Does the ligand release GH in a native cell? | GH concentration in medium by immunoassay | Vehicle; a receptor antagonist; a GHRH-receptor ligand for comparison |
| Isolated heart or cardiomyocyte models | Are cardiac cells responsive, and through which receptor? | Contractile function, cell survival markers, signaling phosphoproteins | Knock-out or knock-down of the putative receptor; inactive analog |
| CD36-expressing cells and tissues | Does the peptide bind the scavenger receptor CD36? | Photoaffinity labeling, binding competition, lipid-handling markers | CD36-null cells or tissue |
| Comparative secretagogue panels | How does potency differ across the class? | Concentration–response curves, EC50 values | Same cell batch, same day, same diluent |
Receptor binding and signaling assays
The receptor itself was identified in 1996, when Howard and colleagues cloned a G protein-coupled receptor from pituitary and hypothalamus that responded to synthetic GH secretagogues. Three years later Kojima and colleagues isolated ghrelin from stomach as its natural ligand (Kojima and colleagues, 1999). Since then the standard approach for a new secretagogue has been to express the receptor in a heterologous cell line and measure what the ligand does.
For hexarelin the useful readouts are the ones that follow from Gq coupling: a rapid rise in intracellular calcium and accumulation of inositol phosphates. A calcium dye plate read takes minutes, which makes it the usual first step. The design points that decide whether the numbers are interpretable are mostly mundane:
- Use the same cell passage and density for every compound on a panel. Receptor expression drifts with passage, and an EC50 is only comparable within a run.
- Run a full concentration–response curve. Two concentrations cannot distinguish a partial agonist from a weak full agonist.
- Include a no-receptor control line. Calcium signals from endogenous receptors are common and are exactly what a parental line reveals.
- Keep the vehicle identical across wells. If the stock was made in bacteriostatic water, benzyl alcohol is present in the vehicle and must be matched in the control wells.
For a head-to-head view of receptor-level behavior across the class, see hexarelin vs GHRP-2 and hexarelin vs ipamorelin.
Pituitary GH-release studies
Hexarelin was characterized early as a GH-releasing hexapeptide. Ghigo and colleagues described its GH-releasing activity in a 1994 report that compared routes of exposure (Ghigo and colleagues, 1994), and the compound was then used as a reference secretagogue in many comparative studies. In a bench setting the question is simpler: if dispersed pituitary cells or a pituitary slice are exposed to the peptide, how much GH appears in the medium, and does a GHS-R1a antagonist block it?
Two features of these experiments cause most of the avoidable noise. First, secretion is pulsatile and state-dependent, so time-matched vehicle controls matter more than the absolute numbers. Second, a secretagogue and a GHRH-receptor ligand act through different receptors and can interact, so any combination arm needs its own single-agent arms. The reasoning behind that design is set out in growth hormone secretagogues vs HGH.
Cardiac and cardiomyocyte models
A distinctive strand of hexarelin literature concerns heart tissue. Locatelli and colleagues reported cardiac effects of hexarelin in rats that did not depend on GH (Locatelli and colleagues, 1999), a finding that prompted the search for binding sites in cardiac tissue. Pettersson and colleagues examined natural and synthetic secretagogues, ghrelin and hexarelin among them, in H9c2 cardiomyocytes (Pettersson and colleagues, 2002), which gave a cultured-cell counterpart to the whole-organ work.
The model choice shapes the evidence. A cultured H9c2 line is easy to handle and gives clean signaling readouts, but it is a cell line from embryonic rat heart and will not reproduce adult contractile behavior. An isolated perfused heart preserves function but offers few replicates per day. Whichever model is used, report which one, the species and the incubation time, since results from the two are not interchangeable.
CD36 as a second binding partner
Bodart and colleagues proposed that CD36, a scavenger receptor, mediates part of the cardiac action of growth hormone-releasing peptides (Bodart and colleagues, 2002). Demers and colleagues then used photoaffinity labeling to map the peptide binding site on CD36 (Demers and colleagues, 2004). A later study used a GH-releasing peptide in white adipocytes and tied its action to CD36 and mitochondrial biogenesis markers (Rodrigue-Way and colleagues, 2007).
For a laboratory the lesson is about specificity. A response to hexarelin in a cell type is not proof of GHS-R1a involvement. The attribution is only secure when the receptor has been removed (knock-out, knock-down or a CD36-null preparation) and the response disappears. Conversely, a peptide that engages two receptors can be a useful tool if the experiment is built to separate them.
Controls that make results interpretable
| Control | Purpose | Common mistake |
|---|---|---|
| Vehicle matched to the stock diluent | Shows the diluent does not move the readout | Using plain buffer when the stock contains benzyl alcohol |
| Reference agonist | Confirms the system responds at all | Skipping it, then being unable to explain a flat result |
| Receptor-negative cells or tissue | Separates receptor-mediated from non-specific signal | Assuming the parental line is receptor-free without testing |
| Antagonist arm | Shows the receptor is necessary | Antagonist applied after, not before, the agonist |
| Aged-stock comparison | Detects loss of activity in stored solution | Never comparing fresh with stored stock |
Preparing hexarelin for these assays
Let the sealed vial reach room temperature before opening so that condensation does not wet the solid. Add the chosen diluent down the glass wall, swirl gently, and let the vial stand until clear. Bacteriostatic water suits a multi-entry stock; sterile water suits aliquots frozen the same day. The step-by-step reasoning is in how to reconstitute a lyophilized peptide, and shelf-life questions are covered in how long reconstituted peptides last. No validated shelf life for reconstituted hexarelin has been published, so a laboratory that needs an exact concentration after days or weeks should freeze single-use portions or re-verify by HPLC. Ready-made concentration tables are deliberately not given here: the figure that matters is the one calculated for your plate and your stock.
Limits of the published evidence
Most of the foundational hexarelin literature is from the 1990s and early 2000s. Assay technology has moved on, and few studies used the modern panel of receptor-negative controls described above. A reader should regard the cardiac and CD36 findings as hypotheses about mechanism that were supported in specific models, not as settled facts about every tissue. Study design guidance for a new project is easier to adapt from the overview at hexarelin research overview, and a plain-language introduction is at what is hexarelin. Material is available through the research catalog for laboratory research use only.
Related reading
- Hexarelin research overview
- What is hexarelin?
- Hexarelin vs GHRP-2
- Hexarelin purity testing
- Where to buy hexarelin for research
Frequently asked questions
What is hexarelin used for in research?
Published studies have used it as a GHS-R1a agonist in binding and signaling assays, as a reference secretagogue in GH-release experiments, and as a probe in cardiac-tissue and CD36 studies. The product is supplied for laboratory research use only.
What receptor does hexarelin act on?
It is an agonist of the growth hormone secretagogue receptor GHS-R1a, the receptor for which ghrelin is the natural ligand. Separate work has shown that it can also bind the scavenger receptor CD36.
Which cell lines are used for hexarelin assays?
Cell lines engineered to express GHS-R1a are used for binding and calcium assays, and H9c2 cardiomyocytes have been used for cardiac signaling work. Parental lines without the receptor serve as negative controls.
How should hexarelin be reconstituted for an assay?
Bring the vial to room temperature, add diluent slowly down the wall, swirl without shaking and let it stand until clear. Choose bacteriostatic water for a multi-entry stock or sterile water for single-use frozen portions.
How is the stock concentration calculated?
Divide the vial mass by the diluent volume (c = m / V). The reconstitution calculator does the arithmetic and avoids unit slips; record the figures in the notebook.
What does the hexarelin vial contain?
The product page lists a 5 mg lyophilized powder, purity ≥98% by HPLC, with the formula C47H58N12O6 and the sequence His-D-2-methyl-Trp-Ala-Trp-D-Phe-Lys-NH2.
How should hexarelin be stored?
Refrigerate at 2–8 °C, use −20 °C for long-term holding, and protect from heat, moisture and light. Divide reconstituted stock into single-use portions if it will be frozen.
Does hexarelin act only through GHS-R1a?
No. Published work points to CD36 as an additional binding partner, so a response is only attributable to GHS-R1a when the receptor has been removed or blocked and the response is lost.
Why include a reference agonist in the assay?
It proves the cells respond at all. Without it, a flat result with hexarelin cannot be told apart from a failed cell preparation.
Is hexarelin the same as GHRP-6?
No. Both are GH-releasing hexapeptides, but hexarelin carries a 2-methyl-D-tryptophan and a different sequence. Comparisons between them are described in the hexarelin vs GHRP-6 research comparison.
Related reading: Hexarelin Research Profile: Chemistry and Key Studies, Hexarelin Side Effects in Research: What Studies Report, Hexarelin and the Ghrelin Receptor GHS-R1a Explained.
References
- Howard AD, Feighner SD, Cully DF, et al. A receptor in pituitary and hypothalamus that functions in growth hormone release. Science. 1996;273(5277):974-977. doi:10.1126/science.273.5277.974
- Kojima M, Hosoda H, Date Y, Nakazato M, Matsuo H, Kangawa K. Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature. 1999;402(6762):656-660. doi:10.1038/45230
- Ghigo E, et al. Growth hormone-releasing activity of hexarelin, a new synthetic hexapeptide, after intravenous, subcutaneous, intranasal, and oral administration in man. J Clin Endocrinol Metab. 1994;78(3):693-698. doi:10.1210/jc.78.3.693
- Locatelli V, et al. Growth hormone-independent cardioprotective effects of hexarelin in the rat. Endocrinology. 1999;140(9):4024-4031. doi:10.1210/en.140.9.4024
- Pettersson I, Muccioli G, Granata R, et al. Natural (ghrelin) and synthetic (hexarelin) GH secretagogues stimulate H9c2 cardiomyocyte cell proliferation. J Endocrinol. 2002;175(1):201-209. doi:10.1677/joe.0.1750201
- Bodart V, Febbraio M, Demers A, et al. CD36 mediates the cardiovascular action of growth hormone-releasing peptides in the heart. Circ Res. 2002;90(8):844-849. doi:10.1161/01.res.0000016164.02525.b4
- Demers A, McNicoll N, Febbraio M, et al. Identification of the growth hormone-releasing peptide binding site in CD36: a photoaffinity cross-linking study. Biochem J. 2004;382(2):417-424. doi:10.1042/bj20040036
- Rodrigue-Way A, Demers A, Ong H, Tremblay A. A growth hormone-releasing peptide promotes mitochondrial biogenesis and a fat burning-like phenotype through scavenger receptor CD36 in white adipocytes. Endocrinology. 2007;148(3):1009-1018. doi:10.1210/en.2006-0975
